Comparative Study of 3 Portable Oxygen Concentrators During a 6-minute Walk Test in Patients With Chronic Lung Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01653730 |
Recruitment Status :
Completed
First Posted : July 31, 2012
Last Update Posted : July 31, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Background: Portable oxygen concentrators (POCs) featuring the latest integrated oxygen conserving devices (OCDs) provide greater patient accessibility and mobility during ambulation and travel. Recent POCs are compact, lightweight, battery-operated, and require no refill-time, thus meeting patients' clinical and lifestyle needs. There is, however, a lack of research on the clinical performance of the latest POCs that could help to determine their ability to maintain patients' oxygen saturations ≥ 90 % during exercise.
Aim: The purpose of this study is to compare the ability of three POCs, with maximum oxygen production capabilities of 950 to 3000 ml per minute, to maintain oxygen saturations ≥ 90 % in patients with chronic lung disease during exercise.
Method: Six minute walk tests (6-MWTs) will be administered in order to measure oxygen saturations by pulse oximetry (SpO2) in up to 20 patients with a diagnosis of either Chronic Obstructive Pulmonary Disease (COPD), or Pulmonary Fibrosis (PF) with documented exertional oxygen desaturations of ≤ 85% on room air. All participants will participate in 4 different 6-minute walk tests: the first will be a control walk performed with the participants' current oxygen system set at their prescribed exertional flow rate. Then, the participants will perform a walk test with each of the three POCs set at the units' maximum pulse dose setting. The order in which the participants use the POCs will be randomly assigned using a sequence generator.
Hypothesis: It is hypothesized that all three POCs will provide oxygen saturations ≥ 90 % during exercise in patients with chronic lung disease with moderate to severe exertional oxygen desaturation.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Chronic Obstructive Lung Disease Pulmonary Fibrosis | Device: Eclipse 3 portable oxygen concentrator Device: EverGo portable oxygen concentrator Device: iGo portable oxygen concentrator | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 24 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | A Comparative Pilot Study of the Efficacy of Three Portable Oxygen Concentrators During a 6-Minute Walk Test in Patients With Chronic Lung Disease |
Study Start Date : | February 2010 |
Actual Primary Completion Date : | August 2010 |
Actual Study Completion Date : | August 2010 |

Arm | Intervention/treatment |
---|---|
Experimental: Eclipse 3 portable oxygen concentrator
Use of the Eclipse 3 portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
|
Device: Eclipse 3 portable oxygen concentrator
Other Name: Eclipse 3 (SeQual Technologies, San Diego, CA, USA) |
Experimental: iGo portable oxygen concentrator
Use of the iGo portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
|
Device: iGo portable oxygen concentrator
Other Name: iGo (DeVillbiss Healthcare, Summerset, PA, USA) |
Experimental: EverGo portable oxygen concentrator
Use of the iGo portable oxygen concentrator set at maximum pulse-dose setting 10-minutes prior to, and during a 6-minute walk test.
|
Device: EverGo portable oxygen concentrator
Other Name: EverGo (Respironics Inc., Murrysville, PA, USA) |
No Intervention: Control portable oxygen concentrator
6-minute walk test completed using each patient's own oxygen delivery system set at their usual oxygen prescription for exercise
|
- Change in saturation of oxygen in the blood after a 6-minute walk test [ Time Frame: During study session 2: immediately before beginning (pre-) and immediately after finishing (post-) each of four 6-minute walk tests ]For patient safety oxygen saturation was monitored throughout each 6-minute walk test using pulse oximetry. Pre- and post-walk values were captured as the primary outcome measure.
- Total distance walked [ Time Frame: During study session 2: immediately after finishing (post-) each of four 6-minute walk tests ]
- Change in Dyspnea ratings after a 6-minute walk test [ Time Frame: During study session 2: immediately before beginning (pre-) and immediately after finishing (post-) each of four 6-minute walk tests ]Measured with the modified 10-point Borg scale
- Patient preference ratings [ Time Frame: During study session 2: immediately after finishing (post-) each of four 6-minute walk tests ]Measured using a self-report questionnaire where patients were asked to indicate how much they agreed with statements about the device they had just used.
- Walk time spent with oxygen saturation greater than or equal to 90% [ Time Frame: During study session 2: immediately after finishing (post-) each of four 6-minute walk tests ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Existing diagnosis of chronic obstructive lung disease or pulmonary fibrosis
- completed the pulmonary rehabilitation program at The Ottawa Hospital Rehabilitation Centre between January 30th 2008 and March 31st 2011
- medically stable
- medical prescription for long term oxygen therapy
- 18 years or older
Exclusion Criteria:
- non-ambulatory
- not independent for activities of daily living
- not active in the community
- show limited improvement with any level of continuous oxygen flow rate
- require more than 6 litres per minute of oxygen on continuous flow during exertion
- experienced an exacerbation of their respiratory medical condition over the last 6 weeks, or have not fully recovered from a recent exacerbation
- have moderate to severe orthopaedic or neurological conditions limiting their ability to walk
- have any other impairments that could affect the consistency of the 6-minute walk test
- have severe co-morbid conditions
- are limited by their cardiac condition or have been diagnosed with a cardiac condition since completion of their pulmonary rehabilitation
- severe cognitive or memory deficit
- speak neither French nor English

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01653730
Canada, Ontario | |
The Ottawa Hospital Rehabilitation Centre | |
Ottawa, Ontario, Canada, K1H 8M2 |
Principal Investigator: | Lyne Lavallée, BSc(PT) | The Ottawa Hospital Rehabilitation Centre | |
Principal Investigator: | Carole Leblanc, RRT | The Ottawa Hospital Rehabilitation Centre | |
Principal Investigator: | Doug McKim, MD | The Ottawa Hospital |
Responsible Party: | Ottawa Hospital Research Institute |
ClinicalTrials.gov Identifier: | NCT01653730 |
Other Study ID Numbers: |
POC-325 |
First Posted: | July 31, 2012 Key Record Dates |
Last Update Posted: | July 31, 2012 |
Last Verified: | July 2012 |
portable oxygen concentrator 6-minute walk test chronic obstructive lung disease pulmonary fibrosis long term oxygen therapy |
Lung Diseases Pulmonary Fibrosis Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive |
Fibrosis Pathologic Processes Respiratory Tract Diseases |